Nabla Secures $70M in Series C Funding to Revolutionize Healthcare with AI Copilot Agents

Paris-based startup Nabla has made waves in the healthcare technology sector by raising $70 million in a Series C funding round led by Germany's HV Capital. Announced on June 17, 2025, this significant investment brings the company's total funding to $120 million, positioning Nabla as a frontrunner in integrating artificial intelligence into clinical workflows.

Nabla's flagship product, the AI Copilot, is designed to support doctors and medical staff by automating tasks such as clinical note-taking and streamlining electronic health record (EHR) workflows. This ambient AI assistant is already utilized by over 85,000 clinicians across more than 130 organizations, demonstrating its growing impact on frontline care teams.

With the fresh infusion of capital, Nabla aims to expand its mission of restoring the human connection in healthcare. The company plans to develop personalized AI agents that go beyond documentation to assist with broader clinical workflows, ultimately enhancing patient care and reducing administrative burdens for healthcare professionals.

The funding round, supported by investors like Highland Europe, underscores the growing confidence in AI-driven solutions for healthcare challenges. Nabla's innovative approach promises to transform how clinicians interact with technology, allowing them to focus more on patient engagement rather than paperwork.

As the healthcare industry continues to grapple with burnout and inefficiencies, Nabla's technology offers a glimmer of hope. By automating repetitive tasks, the AI Copilot empowers medical staff to dedicate more time to meaningful patient interactions, potentially improving outcomes and satisfaction.

Looking ahead, Nabla is set to accelerate its global expansion and further refine its agentic AI capabilities. This latest funding milestone marks a pivotal moment for the company as it strives to bring cutting-edge solutions to every corner of the healthcare ecosystem.